Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction

European Respiratory Journal

Volumn 15, Issue 4, 2000, Pages 693-699

  Richter, K ^a   Jorres R A ^a   Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Asthma; Cold air induced bronchoconstriction; Leukotriene receptor antagonist; Leukotrienes; Zafirlukast

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHOSPASM; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLD AIR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADULT; AIR; ANALYSIS OF VARIANCE; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; COLD; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PROBABILITY; RESPIRATORY FUNCTION TESTS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 0343092062     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.15d12.x     Document Type: Article

References (36)

1. Pliss LB, Ingenito EP, Ingram RH, Pichurko B. Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma. Am Rev Respir Dis 1990; 142: 73-78.
2. Togias AG, Naclerio R, Peters S, et al. Local generation of sulfidopeptide leukotrienes upon nasal provocation with cold dry air. Am Rev Respir Dis 1986; 133: 1133-1137.
3. 4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89: 1111-1119.
4. 4 antagonist. Am Rev Respir Dis 1992; 145: 746-749.
5. 4-receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413-1418.
6. 4-receptor antagonist. N Engl J Med 1990; 323: 1736-1739.
7. 4 levels in asthmatic patients. Eur Respir J 1998; 11: 617-623.
8. Robuschi M, Riva E, Fuccella LM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F) 104,353. Am Rev Respir Dis 1992; 145: 1285-1288.
9. Israel E, Juniper EF, Callaghan JT, et al. Effect of a leukotriene antagonist, LY 171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis 1989; 140: 1348-1353.
10. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740-1744.
11. Israel E, Lavins BJ, Miller CJ, Cohn J. Effect of zafirlukast (20 and 40 mg) on cold-air-induced bronchoconstriction in patients with bronchial asthma. Eur Resp J 1996; 9 (Suppl 23): S51.
12. Boulet LP, Bai TR, Miller CJ, et al. Effect of zafirlukast on cold-air-induced bronchoconstriction in patients with asthma. Eur Respir J 1996; 9 (Suppl 23): S273.
13. Jorres RA, Nowak D, Kirsten D, Gronke L, Magnussen H. A short protocol for methacholine provocation testing adapted to the Rosenthal-Chai dosimeter technique. Chest 1997; 111: 866-869.
14. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
15. Nowak D, Kuziek G, Joerres R, Magnussen H. Comparison of refractoriness after exercise and hyperventilation-induced asthma. Lung 1991; 169: 57-67.
16. Nowak D, Joerres R, Rabe KF, Luethke M, Wiessmann J, Magnussen H. Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. Eur J Clin Pharmacol 1992; 43: 591-595.
17. Malo JL, Cartier A, L'Archeveque J, Ghezzo H, Martin RR. Cold air inhalation has a cumulative bronchospastic effect when inhaled in consecutive doses for progressively increasing degrees of ventilation. Am Rev Respir Dis 1986; 134: 990-993.
18. Runyon RP. Nonparametric statistics: a contemporary approach. Reading, MA, USA, Addison-Wesley Publishing Company 1977; 110-112.
19. Magnussen H, Reuss G, Jörres R, Aurich R. Duration of the effect of a single dose of azelastine on histamin-induced bronchoconstriction. J Allergy Clin Immunol 1989; 83: 467-471.
20. Liu MC, Dubé LM, Lancaster J and the Zileuton study group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6 month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859-871.
21. Deal EC Jr., McFadden ER Jr., Ingram RH Jr., Strauss RH, Jaeger JJ. Role of respiratory heat exchange in production of exercise-induced asthma. J Appl Physiol 1979; 46: 467-475.
22. Cartier A, Ghezzo H, L'Archeveque J, Trudeau C, Malo JL. Duration and magnitude of action of 50 and 100 μg of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma. J Allergy Clin Immunol 1993; 92: 488-492.
23. Malo JL, Ghezzo H, Trudeau C, L'Archeveque J, Cartier A. Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immunol 1992; 89: 567-574.
24. Tessier P, Cartier A, L'Archeveque J, Ghezzo H, Martin RR, Malo JL. Within- and between-day reproducibility of isocapnic cold air challenges in subjects with asthma. J Allergy Clin Immunol 1986; 78: 379-387.
25. Accolate Product Monograph. March 1996, Macclesfield, England, Zeneca Pharmacouticals.
26. 4-receptor antagonist cinalukast. J Allergy Clin Immunol 1997; 99: 210-215.
27. ™), sodium cromoglycate or placebo on exercise-induced bronchoconstriction in asthmatic adolescents. Am J Respir Crit Care Med 1997; 155: A665.
28. Fischer AR, Rosenberg MA, Roth M, Loper M, Jungerwirth S, Israel E. Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold air. Thorax 1997; 52: 1074-1077.
29. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990, 142: 112-119.
30. Wenzel SE, Westcott JY, Larsen GL. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991; 87: 540-548.
31. 4 from the urine of patients with airways obstruction. Am Rev Respir Dis 1992; 146: 104-108.
32. 4 as a marker of nocturnal asthma. Am Rev Respir Dis 1992; 145: A16.
33. 4 excretion in exercise induced asthma. J Appl Physiol 1992; 73: 743-748.
34. 4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 1991; 144: 1411-1413.
35. Broide DH, Eisman S, Ramsdell JW, Ferguson P, Schwartz LB, Wasserman SI. Airway levels of mast cell-derived mediators in exercise-induced asthma. Am Rev Respir Dis 1990; 141: 563-568.
36. Way W, Sasagawa M, Takemoto A, et al. Sputum leukotrienes in chronic airway diseases and bronchial asthma attacks. Nippon Kyobu Shikkan Gakkai Zasshi 1992; 30: 1695-1703.